康惠製藥(603139.SH):近幾年投資主要圍繞醫藥產業進行,涉及中藥行業上下游
格隆匯5月5日丨有投資者在投資者互動平台向康惠製藥(603139.SH)提問,“公司2022年業績預吿叫人痛心,請問公司最近兩三年收購的多家企業,這些公司2022年不能完成業績承諾的話,如何補償上市公司全體股東”
康惠製藥回覆稱,公司近幾年投資主要圍繞醫藥產業進行,涉及中藥行業上下游、醫藥化藥中間體領域。公司管理層深知投資風險與回報並存的客觀事實,自上市以來,公司的投資行為始終保持着謹慎、為廣大投資者負責的態度,目前公司收購的控股子公司多為淨資產收購,同時採取了簽訂業績承諾的方式以保障股東利益。這些公司若未完成業績承諾,公司將依據投資協議約定要求承諾方履行補償義務,後續公司將根據信息披要求及時履行信息披露義務,請您持續關注公司相關公吿。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.